Evidence map›Paper›PMID 38379326›Full record

ArticleCancer medicine2024

Prognostic implications of HER2NEU-low in metastatic breast cancer.

Zachary Neubauer, Shaakir Hasan, Robert H Press, Arpit M Chhabra, Jana Fox, Richard Bakst, Charles B Simone, J Isabelle Choi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zachary NeubauerThomas Jefferson School of Medicine, Philadelphia, Pennsylvania, USA.ORCID 0009-0006-4497-2866
Shaakir HasanNew York Proton Center, New York, New York, USA.ORCID 0000-0002-3627-8798
Robert H PressNew York Proton Center, New York, New York, USA.ORCID 0000-0002-3297-3945
Arpit M ChhabraNew York Proton Center, New York, New York, USA.
Jana FoxMontefiore Medical Center, Department of Radiation Oncology, New York, New York, USA.
Richard BakstMount Sinai Medical Center. Department of Radiation Oncology, New York, New York, USA.
Charles B SimoneNew York Proton Center, New York, New York, USA.ORCID 0000-0002-0867-3694
J Isabelle ChoiNew York Proton Center, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe explored characteristics and clinical outcomes of HER2-negative and HER2-low metastatic breast cancers using real-world data.

methodsWe queried the National Cancer Database to identify MBC patients that were HER2-low or HER2-negative per immunohistochemical staining. A binomial regression analysis identified demographic and clinical correlates of each subtype. A Cox multivariable regression analysis (MVA) and propensity-match analysis were performed to identify correlates of survival.

resultsExcluding missing data, 24,636 MBC patients diagnosed between 2008 and 2015 were identified; 27.9% were HER2-negative and 72.1% were HER2-low. There were no relevant demographic differences between the groups. HER2-low tumors were half as likely to have concomitant hormone receptor-positive status (p < 0.01). The 3-year survival rate among hormone receptor-negative patients was 33.8% for HER2-low and 32.2% for HER2-negative (p < 0.05), and 60.9% and 55.6% in HER2-low and HER2-negative cases among hormone receptor-positive patients (p < 0.05), respectively. HER2-low cases were associated with better survival on MVA (HR =0.95, 95% CI 0.91-0.99) and remained superior with propensity-matching (HR = 0.92, 95% CI 0.89-0.96). In a subset analysis isolated to hormone receptor-positive cases, HER2-low remained correlated with improved survival (HR = 0.93, 95% CI 0.89-0.98) with propensity-matched MVA. Correlates of worse survival include older age as a continuous variable (HR = 1.02, 95% CI 1.02-1.02) and Black race (HR = 1.26, 95% CI 1.20-1.32) [all p < 0.01].

conclusionsIn the largest such analysis performed to date, our study demonstrates a small but statistically significant association with improved survival for HER2-low tumors compared to HER2-negative tumors in MBC.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansPrognosisErb-b2 Receptor Tyrosine KinasesHER2 expressionhormone receptor statusmetastatic breast cancerNational Cancer Databaseoverall survival

Identifiers

PMID38379326
PMCPMC10839127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.